短小棒状杆菌与顺铂胸腔注射对恶性胸腔积液疗效的对比研究  

A randomized trial comparing corynbacterium paruum versus cisplatin for the treatment of patients with malignant hydroperichestcavity

作　　者：洪永青[1] 王立新[1] 高金瑜[1] 

机构地区：[1]南京医科大学附属淮安市第一人民医院呼吸科,223300

出　　处：《临床肺科杂志》2009年第2期203-204,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的评价短小棒状杆菌和顺铂治疗恶性胸腔积液的疗效及安全性。方法可评价疗效的恶性胸腔积液患者随机分为治疗组与对照组。治疗组20例,采用单J管持续胸腔引流后注入短小棒状杆菌,每周一次共2次。对照组18例,采用单J管持续胸腔引流后注入顺铂,每周一次共2次。结果治疗组和对照组有效率分别为50.0%和55.6%(P=0.732),差异无统计学意义。治疗组的Ⅰ～Ⅱ度中性粒细胞减少发生率(35.0%)低于对照组(61.1%)。治疗组发热发生率(55.0%)明显高于对照组(11.1%)。治疗组胃肠反应发生率(15.0%)明显低于对照组(44.4%),以上三者差异均有统计学意义。两组患者各项生活质量评分差异无统计学意义。结论短小棒状杆菌治疗恶性胸腔积液疗效确切,患者耐受性良好,为恶性胸腔积液的治疗提供了一种新的选择。Objective To evaluate the difference of efficacy, side effect and quality of life in malignant hydroperichesteavity patients treated with corynbacterium paruum or eisplatin. Methods Eligible patients were randomly assigned to study subjects and controls. In the study subjects, 20 cases were treated with eorynbaeterium paruum after who was carried out on follow-up who received the simple J tube. Results For the study subjects and for the controls, respectively, the response rates were 50. 0% and 55.6% , median TTP were 5.3 months and 4.5 months, 1 year survival rate were 60. 5% and 54. 6%. Grade Ⅰ -Ⅱ neuro-sensory toxicity occurred significantly more frequent in the study subjects than in the controls. There was no statistical difference between the two groups regarding quality of life. Conclusion Due to good effieancy and talerability, the corynbaeterium paruum intracavitary injection regimen offers a new candidate for treating malignant hydroperiehesteavity.

关 键 词：胸腔积液 短小棒状杆菌 顺铂 

分 类 号：R730.5[医药卫生—肿瘤]